{"id":"W3024966661","doi":"10.1016/j.clgc.2020.05.006","title":"Safety and Efficacy of Nivolumab in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study","year":2020,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":106,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Genentech; Bristol-Myers Squibb Canada; Ignyta; Eli Lilly and Company; Ono Pharmaceutical; Astellas Pharma; Daiichi-Sankyo; Pfizer; Moderna; Five Prime Therapeutics; Mirati Therapeutics; Clovis Oncology; Roche; Karyopharm Therapeutics; Novartis; AbbVie; Sanofi; MedImmune; Merck; GlaxoSmithKline; British Microcirculation Society; Amgen; AstraZeneca; Bristol-Myers Squibb","keywords":"Medicine; Chromophobe cell; Nivolumab; Internal medicine; Renal cell carcinoma; Adverse effect; Regimen; Gastroenterology; Clinical endpoint; Phases of clinical research; Rash; Clear cell; Urology; Surgery; Oncology; Chemotherapy; Cancer; Clinical trial; Immunotherapy","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002999578,0.0003549968,0.0009041327,0.00004236763,0.00008449611,0.00001237621,0.0002385111,0.0001271347,0.00006174479],"category_scores_gemma":[0.0001366035,0.0002302298,0.0001640842,0.0003048501,0.0002128034,0.00007828994,0.0002203309,0.0006191045,0.00001558638],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001277427,"about_ca_system_score_gemma":0.0002541585,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000411137,"about_ca_topic_score_gemma":0.0000406073,"domain_scores_codex":[0.9967132,0.0002777446,0.001265562,0.0008871574,0.000494686,0.0003617072],"domain_scores_gemma":[0.9976601,0.0006394422,0.0004532071,0.0007024819,0.0001552508,0.0003894974],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1470147,0.009069576,0.8290372,0.00009001853,0.0001600832,0.0005643803,0.002405731,0.000206674,0.0009450152,7.039892e-8,0.0006639077,0.009842693],"study_design_scores_gemma":[0.1107146,0.02151756,0.8639756,0.00009436046,0.0004214252,8.154165e-7,0.0004864748,0.0002020253,0.001902357,7.363391e-7,0.0004668115,0.0002172145],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9952948,0.0008887787,0.000004127338,0.0005950772,0.0001405041,0.002119636,0.0002760741,0.00002568517,0.0006553133],"genre_scores_gemma":[0.9983612,0.0002151722,0.0003074085,0.0003497112,0.0003641889,0.00003905522,0.0001079018,0.00005679754,0.0001985564],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03630004,"threshold_uncertainty_score":0.9388497,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03434760163426389,"score_gpt":0.3187661217690864,"score_spread":0.2844185201348225,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}